ANN ARBOR, Mich., May 17, 2016 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM), a veterinary pharmaceutical company, today announced the completion of a research collaboration agreement that includes an exclusive worldwide animal health license option with CTX Technology, Inc. (“CTX”) for their peptide-based skin penetration platform technology.
The CTX-proprietary technology represents a new approach for improved topical delivery of a wide range of active ingredients, which offers many advantages in veterinary medicine including ease of application and enhanced effectiveness of prescribed therapeutics to maximize companion animal care and treatment.
“This is an opportunity for Zomedica to complement its own novel drug delivery platform and collaborate on other alternative drug deliveries not previously considered for the companion animal space,” stated Zomedica Chief Operations Officer Stephanie Morley, DVM. “This platform technology aligns with Zomedica’s mission to provide products that help clinical veterinarians lower costs, increase productivity, and grow practice revenue while better serving the animals in their care.”
Under the terms of the agreement, which was preceded by the completion of initial due diligence by Zomedica to assess the technology’s scientific merits and applications in the animal health space, CTX grants Zomedica the:
- Option for an exclusive, worldwide animal health license;
- Potential for jointly developed intellectual property;
- Opportunity to receive milestone payments and/or royalties associated with aforementioned jointly developed intellectual property that impacts human field-of-use.
In addition, the research collaboration will proceed by way of a Joint Research Committee comprised of CTX-appointed alternative drug delivery experts and Zomedica-appointed animal health experts.
“This collaboration presents a unique opportunity to work with world-renowned scientists and entrepreneurs Dr. Robert Langer, Dr. Samir Mitragotri and Dr. Betty Yu to create safe and effective solutions that support veterinarians’ high medical standards and aids productivity,” stated Zomedica Chief Medical Officer William MacArthur, MS, DVM.
The agreement calls for Zomedica to provide CTX with a one-time upfront cash payment for a technology access fee and a royalty on net sales, though specific financial terms of the agreement are subject to confidentiality restrictions. Zomedica shall coordinate, monitor and fund the research plan associated with commercializing the peptide platform technology. The agreement will potentially allow Zomedica to strengthen its veterinary-focused product portfolio and asset valuation.
About Zomedica
With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical company targeting health and wellness solutions for companion animals (canine, feline and equine) through a ground-breaking approach that focuses on the unmet needs of clinical veterinarians. Zomedica is building a diversified portfolio of products comprised of the discovery, development and commercialization of innovative drugs alongside novel drug delivery systems, devices and diagnostics. With multiple clinical veterinarians in executive management, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: sign up for investor, product and service alerts at www.ZOMEDICA.com
- LinkedIn: www.linkedin.com/company/zomedica
About CTX Technology Inc.
CTX Technology Inc., based in Tucson, Arizona, is commercializing a proprietary peptide-based skin-penetration platform technology that offers a new approach for improved topical delivery of therapeutics and cosmetics. CTX is engaged in IND-enabling work for a topical cyclosporine formulation for mild-to-moderate psoriasis that it expects to be the first topical disease-modifying therapeutic for the indication without serious adverse systemic side effects. The CTX skin permeation technology has already shown good results in trials with human subjects of cosmetic anti-aging products that will be further developed through commercial partnerships with major consumer product companies.
Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.